On Sept. 8, 2021, National Resilience and Moderna announced an agreement to manufacture drug substance for the Moderna COVID-19 vaccine. Resilience will produce mRNA for the Moderna COVID-19 vaccine at its facility in Mississauga, Ontario in Canada, for distribution worldwide.